Physician profile
Peter N Kaufman
NPI 1548229446
$9,254.74
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,890 · 2020: $1,522 · 2021: $96.41 · 2022: $1,447 · 2023: $2,652 · 2024: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,263 · Education: $36.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,262.86 |
| Education | $36.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,888.05 | 2019-2024 | |
| Alfasigma USA, INC. | $1,000.00 | 2020 | |
| Celgene Corporation | $926.48 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $845.83 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $579.72 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $502.96 | 2019-2024 | Stelara, Tremfya |
| Qol Medical, LLC | $479.24 | 2019-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $371.29 | 2022-2024 | |
| Ardelyx, INC. | $302.72 | 2022-2024 | Ibsrela |
| Daiichi Sankyo INC. | $281.73 | 2019-2024 | Injectafer |
| Pfizer INC. | $254.78 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $245.59 | 2022-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $218.50 | 2023-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $189.45 | 2022 | |
| Ferring Pharmaceuticals INC. | $181.23 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.